{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-004406","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2022-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.353402+00:00","generated_at":"2026-06-27T09:37:03.370486+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Viking Therapeutics Q4 net loss $12.4M; clinical hold on VK0214; cash $202.1M","bullets":["Net loss $12.4M ($0.16/share) for Q4 2021 vs $10.9M ($0.15) year ago; FY net loss $55.0M ($0.71) vs $39.5M ($0.54).","Cash, equivalents, short-term investments $202.1M at Dec 31, 2021, down from $248.4M a year ago.","FDA placed Phase 1b trial of VK0214 (X-ALD) on clinical hold; expects to submit requested preclinical data in Q2 2022.","Phase 1 trial of dual GLP-1/GIP agonist VK2735 initiated; data expected in 2H22.","Phase 2b VOYAGE trial of VK2809 for NASH continuing enrollment; initial data expected by end of 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-004406","json":"https://secwatch.observer/filing/0001564590-22-004406.json","markdown":"https://secwatch.observer/filing/0001564590-22-004406.md","text":"https://secwatch.observer/filing/0001564590-22-004406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000156459022004406/0001564590-22-004406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000156459022004406/vktx-8k_20220209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T09:37:03.370486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}